Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,180 | 2,360 | 19:03 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.06. | JUNSHI BIO (01877): POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
20.06. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON COMPLETION OF PLACING OF NEW H SHARES UNDER ... | 2 | HKEx | ||
20.06. | JUNSHI BIO (01877): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | - | HKEx | ||
SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
20.06. | JUNSHI BIO (01877): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
19.06. | JUNSHI BIO (01877): CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE | - | HKEx | ||
13.06. | JUNSHI BIO Places Shrs at 11.5% Discount to Raise Net HKD1.03B | 1 | AASTOCKS | ||
13.06. | JUNSHI BIO (01877): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
11.06. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JT118 RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION | 2 | HKEx | ||
05.06. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGE IN EQUITY OF THE SHAREHOLDERS ... | 1 | HKEx | ||
29.05. | JUNSHI BIO (01877): FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 20 JUNE 2025 | 3 | HKEx | ||
29.05. | JUNSHI BIO (01877): 2024 ANNUAL REPORTS AND ACCOUNTS 2024 PROFIT DISTRIBUTION PLAN CREDIT LINES FROM FINANCIAL INSTITUTION(S) FOR 2025 DIRECTORS' AND ... | - | HKEx | ||
29.05. | JUNSHI BIO (01877): NOTICE OF THE 2024 ANNUAL GENERAL MEETING | 1 | HKEx | ||
29.05. | JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 1 | HKEx | ||
29.05. | JUNSHI BIO (01877): ANNOUNCEMENT - ADJUSTMENTS TO THE USE OF PROCEEDS FROM THE 2022 ISSUANCE OF A SHARES | - | HKEx | ||
27.05. | Junshi Biosciences Announces Ongericimab's sNDA Approval in China | 334 | GlobeNewswire (Europe) | SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
27.05. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR ONGERICIMAB INJECTION | 3 | HKEx | ||
16.05. | JPMorgan raises Junshi Biosciences rating to neutral | 2 | Investing.com | ||
25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2025 FIRST QUARTERLY REPORT | 3 | HKEx | ||
25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PARTICIPATION IN THE 2024 ANNUAL RESULTS ... | - | HKEx | ||
25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON APPOINTMENT OF SECURITIES AFFAIRS REPRESENTATIVE | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |